Bio-Thera Conducts Simponi Phase III Trial

Study In Psoriatic Arthritis Patients Begins For BAT2506 Golimumab Biosimilar

China’s Bio-Thera Solutions has announced the start of Phase III trials for its BAT2506 proposed biosimilar golimumab rival to Janssen’s Simponi.

Clinical_Trial_Puzzle
Bio-Thera has kicked off a Phase III study for its golimumab biosimilar • Source: Shutterstock

Bio-Thera Solutions has begun Phase III trials for its BAT2506 proposed biosimilar rival to Janssen’s Simponi (golimumab) arthritis treatment.

The Chinese biosimilars specialist said that dosing had begun in a randomized, double-blind, parallel group, active control study to compare...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.